* This product is for research use only. Not intended for use in the treatment or diagnosis of disease.
Despite modern achievements in medical diagnosis and treatment, lung cancer remains the leading cause of cancer death worldwide. Each year, more than one million people die from lung cancer, and less than 10 percent of patients survive for more than five years after a lung cancer diagnosis. Lung cancer includes two major categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 75 percent of all lung cancers, with an overall survival rate of only 15 percent in five years. Advances in immunotherapy and targeted therapies are critical to patients' treatment with lung cancer. In 1972, researchers discovered A549 cells in the tissue of a 52-year-old white male diagnosed with lung cancer. A549 cells are alveolar basal squamous epithelial cells from human lung cancer patients. A549 diffuses substances such as water and electrolytes into the alveoli. A549 also synthesizes lecithin, which contains high levels of unsaturated fatty acids, via the cytidine diphosphate choline pathway. A549 cells have been used to study the changes in related proteins expression, lung cancer drug development, and various respiratory diseases, such as viral infections that cause asthma and smoking-induced emphysema.
BOC Science has developed the A549 transfection reagent. This specific reagent provides the highest transfection efficiency, cell viability, expression levels and lowest cytotoxicity for A549 cells.
|Contents||A549 Transfection Kit includes A549 transfection reagent and transfection enhancer.|
|Storage||Store at 4℃. If stored properly, the reagent is stable for up to 6 months.|
|Shipping||The A549 transfection reagent is supplied in liquid form and is transported at ambient temperature.|
|Transfection Efficiency||At least 90% efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.|
|Use Limitations||For research use only.|